Skip to main content
Clinical Trials/NCT02504593
NCT02504593
Completed
N/A

Novel mHealth Platform to Ensure Quality of Community-based Malaria Diagnosis

Duke University1 site in 1 country100 target enrollmentJuly 2015

Overview

Phase
N/A
Intervention
Not specified
Conditions
Quality Assurance of Malaria Diagnosis
Sponsor
Duke University
Enrollment
100
Locations
1
Primary Endpoint
Percent of RDTs with correct administration and interpretation by CHVs compared across the first and tenth tests
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). The study will lease 10 DRs and rotate them amongst 200 CHVs performing community-based malaria diagnosis through rapid diagnostic testing. The study setting is Bungoma East subcounty and Kiminini subcounty in Kenya. The overall goal is to measure and improve the quality of malaria diagnosis by CHVs using malaria RDTs. The investigators aim for every CHW to exceed 90% sensitivity and specificity and zero operator errors within six months. There are no appreciable risks to the CHV associated with evaluation by the DR device. The investigators' analysis will focus on descriptive statistics of RDT use and accuracy amongst all participating CHVs.

Registry
clinicaltrials.gov
Start Date
July 2015
End Date
April 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All community health volunteers in 10 community units in Bungoma East and 6 community units in Kiminini that have been trained to provide community-based malaria diagnosis through rapid diagnostic testing are eligible.

Exclusion Criteria

  • Any person not meeting the inclusion criteria.

Outcomes

Primary Outcomes

Percent of RDTs with correct administration and interpretation by CHVs compared across the first and tenth tests

Time Frame: 6 months (during which each consenting CHV of the 200 eligible will conduct 10 tests)

The percent of RDTs that were properly conducted and interpreted by CHVs, according to Deki Reader results, comparing across the first and tenth RDTs read with the Deki Reader for each CHV.

Secondary Outcomes

  • Percent of RDTs with a false negative reading by CHVs compared across the first and tenth tests(6 months)
  • Percent of RDTs with a false positive reading by CHVs compared across the first and tenth tests(6 months)
  • Overall specificity (measured as the proportion of negative tests as determined by the DR which the CHVs correctly identify).(6 months)
  • Percent of invalid RDTs not properly identified by CHVs compared across the first and tenth tests(6 months)
  • Percent of RDTs that CHVs performed with an improper test procedure compared across the first and tenth tests.(6 months)
  • Overall sensitivity (measured as the proportion of positive tests as determined by the DR which the CHVs correctly identify).(6 months)

Study Sites (1)

Loading locations...

Similar Trials